Our previous studies show that ESA+CD44+CD24-/low breast cancer cells have stem-like cell characteristics and found that BCSCs on the conventional chemotherapy drug docetaxel, endocrine therapy drugs such as letrozole and targeted therapy trastuzumab, have a certain resistance [24–26]. This evidence concerns the gene CD24 and breast carcinoma.